Analytical Data
-
基因名
VEGFR-2
- Application
-
别名
CD309; FLK1; VEGFR; KDR; A Type III Receptor Tyrosine Kinase; Kinase Insert Domain Receptor; Kinase Insert Domain Receptor; Fetal Liver Kinase-1
-
种属
Human
-
表达系统
HEK293
-
标签
N-His
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
P35968
-
表达区间
Ala20~Glu764
-
分子量
90kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) is a critical receptor in angiogenesis, playing a pivotal role in the regulation of blood vessel growth and maintenance. It is primarily involved in mediating the effects of Vascular Endothelial Growth Factor (VEGF), which is essential for both physiological processes and pathological conditions, such as cancer and cardiovascular diseases. The study of VEGFR-2 recombinant protein has gained significant importance due to its potential therapeutic applications. Understanding the structure and function of VEGFR-2 can facilitate the development of targeted therapies aimed at inhibiting angiogenesis in tumor growth. Additionally, VEGFR-2 is a promising target for monoclonal antibodies and small molecule inhibitors that may improve treatment outcomes in various malignancies. Advances in recombinant protein technology have enabled the production of this protein in a more efficient manner, allowing for detailed studies of its signaling pathways and interactions with ligands. As research progresses, the characterization and functional analysis of VEGFR-2 recombinant proteins continue to provide insights into new treatment modalities, emphasizing the need for continued exploration of this receptor in both basic and translational research.
